At 4 years post-transcatheter aortic valve replacement (TAVR), patients who received the CoreValve, Evolut R or Evolut PRO self-expanding valves continued to show robust clinical outcomes, and better hemodynamic outcomes, in comparison with patients who underwent surgical aortic valve replacement (SAVR) with contemporary surgical valves, a new analysis shows.